CAR-modified cells and the sisyphus myth: A new panacea for lupus?

Garelick D Isenberg DA . Baby you can drive my CAR-T cells. Lupus 2025; 34: 653–656. DOI: 10.1177/09612033251335798.

Edwards JCW Cambridge G . Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology 2005; 44(2): 151–156. DOI: 10.1093/rheumatology/keh446.

Kansal R Richardson N Neeli I , et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 2019; 11(482). DOI: 10.1126/scitranslmed.aav1648.

Müller F Taubmann J Bucci L , et al. CD19 CAR T-cell therapy in autoimmune disease – a case series with follow-up. N Engl J Med 2024; 390(8): 687–700. DOI: 10.1056/NEJMoa2308917.

Illei GG Yarboro CH Kuroiwa T , et al. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis. Rheumatology 2007; 46(6): 952–956. DOI: 10.1093/rheumatology/kem001.

Viallard JF Mercié P Faure I , et al. Successful treatment of lupus with fludarabine. Lupus 1999; 8(9): 767–769. DOI: 10.1191/096120399678840954.

Levine BL Pasquini MC Connolly JE , et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med 2024; 30(1): 338–341. DOI: 10.1038/s41591-023-02767-w.

Muthuvel M Srinivasan H Louis L , et al. Engineering off-the-shelf universal CAR T cells: a silver lining in the cloud. Cytokine 2022; 156: 155920. DOI: 10.1016/j.cyto.2022.155920.

Qin VM D’Souza C Neeson PJ , et al. Chimeric antigen receptor beyond CAR-T cells. Cancers (Basel) 2021; 13(3): 404. DOI: 10.3390/cancers13030404.

ClinicalTrials.gov . A study of MCARH109 in subjects with relapsed or refractory systemic lupus erythematosus (SLE) [Internet]. Bethesda (MD): National Library of Medicine (US), 2022. [cited 2025 Apr 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT05459870